Thyroid Cancer Drugs Market - Global Industry
Insights, Trends, Outlook, and Opportunity Analysis,
2018-2026
In the recent past, increasing number of thyroid cancers were diagnosed at an early stage of
the treatment as several new technologies has arrived with drugs. Advanced treatments resulting
into long term survival, minimum complications of surgery and improved quality of life in a
cost-effective way. The main types of thyroid cancer includes differentiated, medullary, and
anaplastic thyroid cancer. Among these, anaplastic thyroid cancer is characterized with an
aggressive undifferentiated tumor. Apart from these, the other types of thyroid cancer includes
thyroid lymphomas, thyroid sarcomas, parathyroid cancer or other rare thyroid tumors.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1710
Thyroid Cancer Drugs Market Drivers
Increasing prevalence of thyroid cancer is expected to drive growth of the thyroid cancer drugs
market. For instance, according to National Cancer Institute (NCI), 2013-2015 data findings,
around1.2% of men and women are expected to be diagnosed with thyroid cancer at some
point during their lifetime, in the U.S. Moreover, according to the NCI 2018 data findings, in
2018, there were an estimated 53,990 new cases of thyroid cancer and an estimated 2,060
people are expected to die due to thyroid cancer, in the U.S. Moreover, according to Cancer
Research UK, 2015 data findings, in the U.K. there were 3,528 new cases of thyroid cancer
registered in 2015. According to the same source, thyroid cancer accounted to register 1% of all
cancer cases in 2015, which includes 27% of thyroid cancer cases in males, and 73% in
females, in the U.K. Furthermore, according to Cancer Research UK, the lifetime risk of
developing thyroid cancer is around 1 in 480 for men and around 1 in 180 for women, in 2012
in the U.K.
In 2016, according to the American Cancer Society, anaplastic thyroid cancer accounts for 2%
of all thyroid cancers, in North America. FDA granted several programs, in order to increase
availability of drugs to treat serious diseases. In May 2018, Food and Drug Administration